Amendment: SEC Form S-4/A filed by BioCryst Pharmaceuticals Inc.
$BCRX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/15/2025 | $30.00 | Buy | TD Cowen |
| 10/1/2025 | $8.00 | Outperform → In-line | Evercore ISI |
| 4/29/2025 | $20.00 | Overweight | Cantor Fitzgerald |
| 2/25/2025 | $15.00 | Outperform | Wedbush |
| 11/20/2023 | $10.00 | Overweight | JP Morgan |
| 9/18/2023 | $9.00 → $10.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 8/4/2023 | $11.00 | Hold → Buy | Jefferies |
| 7/13/2023 | $10.00 | Neutral → Buy | BofA Securities |
8-K/A - BIOCRYST PHARMACEUTICALS INC (0000882796) (Filer)
8-K - BIOCRYST PHARMACEUTICALS INC (0000882796) (Filer)
8-K - BIOCRYST PHARMACEUTICALS INC (0000882796) (Filer)
4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
3 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
3 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
RESEARCH TRIANGLE PARK, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2025 financial results on Thursday, February 26, 2026. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst is a global biotechn
RESEARCH TRIANGLE PARK, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the compensation committee of BioCryst's board of directors granted 24 newly-hired employees stock options to purchase an aggregate of 251,150 shares, and restricted stock units (RSUs) covering an aggregate of 368,550 shares, of BioCryst common stock. The options and RSUs were granted as of February 2, 2026, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $6.63 per share, which is equal to the closing price
RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has completed its acquisition of Astria Therapeutics, Inc., initially announced on October 14, 2025. The transaction strengthens its position as a leader in hereditary angioedema (HAE) and enhances the company's long-term growth trajectory. BioCryst adds navenibart, a late-stage, long-acting plasma kallikrein inhibitor currently in Phase 3 clinical development, to its HAE portfolio. The potential to be the first HAE therapy with every-three and every-six month dosing, combined with a high level of attack control, positions navenibart to significantly improv
TD Cowen resumed coverage of BioCryst Pharma with a rating of Buy and set a new price target of $30.00
Evercore ISI downgraded BioCryst Pharma from Outperform to In-line and set a new price target of $8.00
Cantor Fitzgerald initiated coverage of BioCryst Pharma with a rating of Overweight and set a new price target of $20.00
4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
RESEARCH TRIANGLE PARK, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new findings from patient-focused research highlighting the burden of current treatments for HAE on pediatric patients under the age of 12 and their caregivers and perspectives on the importance of HAE treatments. The findings will be presented in posters at the 2025 US HAEA National Summit in Baltimore, which is taking place July 10-13, 2025. "For more than a decade, we have been honored to join the HAE patient community at the US HAEA National Summit. It is an opportunity for us to hear directly from them on their hopes and dreams
RESEARCH TRIANGLE PARK, N.C., July 07, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the appointment of Babar Ghias as chief financial officer (CFO) and head of corporate development. Mr. Ghias joins BioCryst from AvenCell Therapeutics, a clinical-stage CAR-T company focused on hematologic malignancies, where he served as CFO since 2022. "Babar brings extensive deal making and operational experience in addition to his previous roles as a CFO at rare disease companies. The addition of these skills and expertise to the leadership team are exactly what we need at this time as we look to deploy capital and accelerate our path to sustainable growth and
RESEARCH TRIANGLE PARK, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company has appointed healthcare investment banking leader Steve Frank to its board of directors. Mr. Frank serves as chairman of global healthcare investment banking at J.P. Morgan. He was previously global group head of worldwide healthcare investment banking at Bear Stearns before it was acquired by J.P. Morgan in 2008. Mr. Frank is a trusted corporate advisor, supporting countless transactions including pharmaceutical, biotechnology, medical device and healthcare services firms. A standout institutional investor before becoming a banker, Mr. Frank direct
SC 13G/A - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)
SC 13G/A - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)
SC 13G/A - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)
RESEARCH TRIANGLE PARK, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2025 financial results on Thursday, February 26, 2026. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst is a global biotechn
—Q3 2025 ORLADEYO net revenue of $159.1 million (+37 percent y-o-y)— —Q3 2025 operating profit of $29.6 million (+285 percent y-o-y); non-GAAP operating profit of $51.7 million (+107 percent y-o-y); continued improvement in non-GAAP operating profit margin from strong operating leverage— —ORLADEYO FY 2025 revenue guidance raised to between $590 to $600 million; FY 2025 non-GAAP operating expense guidance lowered to between $430 to $440 million— —Sale of European ORLADEYO business completed; proceeds used to retire all remaining Pharmakon term debt— —Definitive agreement signed to acquire Astria Therapeutics; transaction expected to close Q1 2026— RESEARCH TRIANGLE
RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2025 financial results on Monday, November 3, 2025. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst Pharmaceuticals is a glob